Monday, 22 June 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 22 June 2026
News

Price moves get mixed PBAC result

Posted 22 June 2026 AM

The PBAC considered a few price changes at its May Intracycle meeting, and was generous in its decisions...mostly.

Pfizer's shot at a higher price for breast cancer drug Tukysa was roundly knocked back. Tukysa was recommended last November in combination with trastuzumab plus capecitabine in the third line for some breast cancers, although with disagreement over comparators resulting in a request for a lower price.

To see the whole article, please login

Popular

PBAC agenda tops 60 submissions
Ex-Novartis boss tells what's next
Aussie book tackles pharma burnout
Leaders 'sleep rough' for a cause
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Access & Reimbursement (1)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (4)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home